Market Intelligence, Clinical Progress, and High-Purity Reagents for Neurodegeneration and Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CDK5 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CDK5/p35 Active Complex / Mutant Protein High purity (>95%), Endotoxin controlled. Sequence Verified. Sf9 Insect Cell Expressed. |
View CDK5 Products |
| Gene Delivery | CDK5 Promise-ORF / Lentivirus Full-length ORF for stable cell lines and overexpression assays. |
View CDK5 Products |
| Benchmark Ab | Anti-CDK5 Recombinant Antibody Sequence-derived recombinant positive control for Western Blot and ELISA. |
View CDK5 Products |
| Validator | CDK5 siRNA Set Target-specific knockdown verification in neuronal or tumor cell lines. |
View CDK5 Products |
| Related Target A | CDK2 Critical counter-screening target. High structural homology to CDK5; selectivity is required to avoid systemic myelosuppression. |
View CDK2 Products |
| Related Target B | MAPT Microtubule-associated protein tau. Primary downstream substrate of hyperactive CDK5/p25 in Alzheimer's disease pathology. |
View MAPT Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Selectivity over CDK2 (ATP-binding pocket homology) | Recombinant human CDK2 and CDK5/p35 proteins available with >95% purity for robust comparative kinase assays. |
| Physiological conformation of active kinase | Co-expressed CDK5/p35 active complex in Sf9 insect cells to ensure correct folding and kinase activity. |
| Lack of Controls | Recombinant benchmark antibodies and kinase-dead mutant proteins included. |
| False Positives | Validated siRNA included for target-specific knockdown verification. |
Live CDK5 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CDK5 therapeutics is intensifying, with major players shifting focus from traditional non-selective pan-CDK inhibitors to highly selective small molecule inhibitors and PROTACs (Proteolysis Targeting Chimeras). As first-generation brain-penetrant molecules reach early clinical stages, the next wave of R&D is targeting the specific disruption of the pathological CDK5/p25 complex while sparing the physiological CDK5/p35 complex to mitigate neurotoxicity.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Selective Kinase Inhibitor) | Lilly, Pfizer, Academic Spin-offs | Alzheimer's Disease, Parkinson's Disease, ALS | Selectivity Assay (Need high-purity CDK5/p35 vs CDK2 proteins) |
| PROTAC (Degrader) | Arvinas, Kymera, Yale University | Glioblastoma, Solid Tumors, Neurodegeneration | Ubiquitination & Degradation Assay (Need stable CDK5/p35 target protein and overexpression Lentivirus) |
| Peptide Inhibitors (p5/CIP) | NIH, Biotech Startups | Alzheimer's Disease, Ischemic Stroke | Protein-Protein Interaction (PPI) Assay (Need native-like CDK5/p25 and CDK5/p35 complexes) |